ClinicalTrials.gov
ClinicalTrials.gov Menu

Comparing Pain and Kinematic Outcomes of Two Gait-Modifying Shoe Interventions

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03760380
Recruitment Status : Not yet recruiting
First Posted : November 30, 2018
Last Update Posted : November 30, 2018
Sponsor:
Collaborator:
Scientific Motion Technologies, Inc.
Information provided by (Responsible Party):
University of Florida

Brief Summary:
This study involves the use of a newly designed shoe device for knee arthritis patients that may help reduce knee pain and improve function.

Condition or disease Intervention/treatment Phase
Arthritis Knee Device: Sole 1 - Neutral Device: Sole 1 - Offset Device: Sole 2 - Neutral Device: Sole 2 - Offset Not Applicable

Detailed Description:

This study involves the use of a newly designed shoe device for knee arthritis patients that may help reduce knee pain and improve function. This is a 2-phase study designed to evaluate knee pain and function in healthy participants with a history of medial knee arthritis.

The purpose of this study is to evaluate: 1. how using the shoe device will affect a person's walking gait and balance over a single day; and 2. how using the shoe device over the course of a 12-week period will affect a person's walking gait and balance.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 54 participants
Allocation: Randomized
Intervention Model: Sequential Assignment
Intervention Model Description:

Phase 1 All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)

Phase 2 Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.

Masking: None (Open Label)
Primary Purpose: Other
Official Title: Pilot Study: Comparing Pain and Kinematic Outcomes of Two Gait-Modifying Shoe Interventions on Knee Osteoarthritis Acutely and Over a 12 Week Period
Estimated Study Start Date : December 2018
Estimated Primary Completion Date : November 1, 2020
Estimated Study Completion Date : November 1, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Arthritis

Arm Intervention/treatment
Experimental: Phase 1 Short Term
Participants will serve as their own control. Questionnaires and gait measures will be collected during an initial visit using the experimental shoe device. All subjects will perform the same procedures with all the experimental interventions (Sole 1 - Neutral, Sole 1--Offset, Sole 2 - Neutral, Sole 2 - Offset)
Device: Sole 1 - Neutral
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability. This is defined as the location which creates the smallest amount of instability.

Device: Sole 1 - Offset
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Device: Sole 2 - Neutral
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The gait-modifying shoes will initially be neutrally aligned to create the smallest amount of instability.This is defined as the location which creates the smallest amount of instability.

Device: Sole 2 - Offset
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Experimental: Phase 2 Long Term
Participants will serve as their own control. Questionnaires, balance, functional and gait measures will be collected during four different visits over a twelve week period (once at baseline visit, 4, 8, and 12 week visits) using the experimental shoe device. Patients will also complete a home walking program using the shoe device over the twelve week period. Subjects will be assigned one of two shoes/soles (either Sole 1-Offset or Sole 2- Offset) for home use.
Device: Sole 1 - Offset
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.

Device: Sole 2 - Offset
Appropriately-designed, stimulatory - but not mechanically supportive -device to enhance control of balance, postural sway and key features of walking gait in arthritic knee patients. The offset sole will be placed in a position that may reduce the knee adduction moment. The anterior elements will be placed 1 cm medially from the neutral position and the posterior pod will be moved 1 cm laterally from the neutral position.




Primary Outcome Measures :
  1. Change in NRS pain (Pain Numeric Rating Scale) score. [ Time Frame: Baseline (Phase 1); Baseline (Phase 2), Week 4, Week 8, Week 12 ]
    Participants selects a whole number (0-10 integers) that best reflects the intensity of his/her pain. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as one can imagine" or "worst pain imaginable").


Secondary Outcome Measures :
  1. Change in WOMAC (Western Ontario and McMaster Universities Arthritis Index) score [ Time Frame: Baseline (Phase 2), Week 4, Week 8, Week 12 ]
    Self-administered questionnaire consisting of 24 items divided into 3 subscales [total score 0-96; subscales from 0-20 (pain)/0-8(stiffness)/0-68(physical function)]. The test questions are scored on a scale of 0-4, which correspond to: None (0), Mild (1), Moderate (2), Severe (3), and Extreme (4).

  2. Change in SF-36 disability score. [ Time Frame: Baseline (Phase 2), Week 4, Week 8, Week 12 ]
    Eight scaled scores, where each scale is directly transformed into a 0-100 scale. The lower the score the more disability.

  3. Change in Timed Up & Go (TUG) Test score. [ Time Frame: Baseline (Phase 2), Week 4, Week 8, Week 12 ]
    Time it takes for participant to rise from chair, walk 3 meters, turn around, walk back and sit down.

  4. Change in Stair Climb time score. [ Time Frame: Baseline (Phase 2), Week 4, Week 8, Week 12 ]
    Time it takes participant to walk up on flight of stairs (12 steps).



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   45 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic, OA-related knee pain
  • Diagnosis of medial compartment knee OA (unilateral or bilateral)
  • Moderate pain of ≥4 out of 10 points while performing a weight-bearing activity
  • Kellgren and Lawrence score of 2, 3, or 4 evidenced on routine, standard-of-care x-ray within the last 2 years prior to enrollment
  • Able to walk unassisted for at least 10 minutes at a time
  • Wear a Women's shoe size of 6.5 to 13 or a Men's shoe size of 5 to 12.

Exclusion Criteria:

  • Patients suffering from acute septic or inflammatory arthritis
  • Unstable cardiovascular, orthopaedic, or neurological conditions, uncontrolled diabetes, or any condition that would preclude exercise in moderate duration, moderate workload trials
  • Received a corticosteroid injection or invasive procedures within prior 6 months of the study
  • History of avascular necrosis in the knee
  • History of knee buckling
  • Joint replacement in any lower extremity joint that has not optimally recovered (e.g. still causes significant pain or affects mobility) as determined by the PI.
  • Experienced more than 3 falls within the last year
  • Currently using any knee brace on a regular basis for the knee pain, with the exception of basic knee sleeves
  • Pathological osteoporotic fracture
  • Severe symptomatic degenerative arthritis in lower limb joints other than the knees
  • Severe back pain, prior spinal fusion or spinal deformity that would affect gait
  • Major cardiac or pulmonary conditions and any orthopedic limitation that precludes their ability to independently walk for 10 minutes or longer
  • Knee flexion contracture greater than 15°
  • Knee flexion of less than 90°
  • Any major injury to either knee within the prior 12 months
  • Currently enrolled in a supervised physical therapy program

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03760380


Contacts
Contact: Michelle Bruner, MS 352-273-7337 bruneml@ortho.ufl.edu
Contact: Rachel Leitz, MS 352-273-7361 leitzrs@ortho.ufl.edu

Locations
United States, Florida
UF & Shands Orthopaedics and Sports Medicine Institute
Gainesville, Florida, United States, 32607
Sponsors and Collaborators
University of Florida
Scientific Motion Technologies, Inc.
Investigators
Principal Investigator: Hari K Parvataneni University of Florida

Responsible Party: University of Florida
ClinicalTrials.gov Identifier: NCT03760380     History of Changes
Other Study ID Numbers: OCR17682
First Posted: November 30, 2018    Key Record Dates
Last Update Posted: November 30, 2018
Last Verified: November 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Device Product Not Approved or Cleared by U.S. FDA: No
Product Manufactured in and Exported from the U.S.: No

Keywords provided by University of Florida:
osteoarthritis (OA)
gait modifying shoe